 SEATTLE, Oct. 1, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today announced topline results from the PRE-VENT trial NCT04404361 of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinibstandard of care versus placebostandard of care in hospitalized patients with severe COVID-19, including patients with and without cancer. 